B.R.A.I.N. Biotechnology Research and Information Network AG (DE:BNN)
XETRA:BNN
Want to see DE:BNN full AI Analyst Report?
Top Page
B.R.A.I.N. Biotechnology Research and Information Network
(XETRA:BNN)
Select Model
Select Model
Rating:50Neutral
Price Target:
€2.50
▲(0.00% Upside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial performance (persistent losses, cash burn, and a sharply weakened 2025 balance sheet with higher leverage) and an unhelpful valuation signal from a negative P/E. These are partially offset by strong technical momentum with the price above key moving averages and a positive MACD, though overbought indicators add near-term risk.
Positive Factors
Gross margin improvement
An improvement in gross margin indicates the company has taken steps to reduce direct costs or improve pricing; if sustained this materially supports a path toward operating leverage, making future profitability easier to achieve even if top-line growth remains challenged.
Negative Factors
Persistent net losses
Ongoing net losses across reporting periods indicate structural unprofitability. This erodes retained earnings and limits reinvestment capacity; sustained losses make it difficult to fund growth internally and increase dependence on external capital, risking dilution and impairing long-term solvency.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin improvement
An improvement in gross margin indicates the company has taken steps to reduce direct costs or improve pricing; if sustained this materially supports a path toward operating leverage, making future profitability easier to achieve even if top-line growth remains challenged.
Read all positive factors
B.R.A.I.N. Biotechnology Research and Information Network (BNN) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€62.05M
Dividend YieldN/A
Average Volume (3M)10.93K
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue Growth-9.17%
EPS Growth-5.52%
CountryDE
Employees296
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.56
Shares Outstanding21,847,494
10 Day Avg. Volume22,707
30 Day Avg. Volume10,926
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.26
Revenue Forecast (FY)€55.79M
B.R.A.I.N. Biotechnology Research and Information Network Business Overview & Revenue Model
Company Description
Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of ...
How the Company Makes Money
null...
B.R.A.I.N. Biotechnology Research and Information Network Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 49.62M | 54.63M | 55.34M | 49.51M | 38.39M |
| Gross Profit | 2.01M | 401.00K | 3.47M | 1.43M | -1.95M |
| EBITDA | -4.17M | -4.23M | -1.98M | -1.30M | 2.01M |
| Net Income | -11.74M | -11.13M | -8.28M | -6.59M | -4.97M |
Balance Sheet | |||||
| Total Assets | 66.34M | 88.74M | 70.94M | 77.99M | 77.74M |
| Cash, Cash Equivalents and Short-Term Investments | 6.32M | 27.29M | 5.41M | 8.53M | 24.65M |
| Total Debt | 24.03M | 29.82M | 25.32M | 10.74M | 2.64M |
| Total Liabilities | 64.50M | 74.85M | 47.92M | 43.74M | 35.91M |
| Stockholders Equity | 1.84M | 12.62M | 21.77M | 29.64M | 38.78M |
Cash Flow | |||||
| Free Cash Flow | -10.76M | -5.31M | -6.86M | -7.57M | -5.17M |
| Operating Cash Flow | -9.23M | -3.58M | -4.22M | -1.49M | -3.91M |
| Investing Cash Flow | -1.56M | -1.69M | 562.00K | -12.69M | -2.18M |
| Financing Cash Flow | -10.14M | 26.99M | 459.00K | -1.97M | 11.57M |
B.R.A.I.N. Biotechnology Research and Information Network Technical Analysis
Positive
2.50
Price Trends
2.83
Positive
2.60
Positive
2.55
Positive
Market Momentum
-0.03
Positive
48.33
Neutral
41.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BNN, the sentiment is Positive. The current price of 2.5 is below the 20-day moving average (MA) of 2.92, below the 50-day MA of 2.83, and below the 200-day MA of 2.55, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 48.33 is Neutral, neither overbought nor oversold. The STOCH value of 41.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BNN.
B.R.A.I.N. Biotechnology Research and Information Network Peers Comparison
UnderperformOutperform
Sector (55)
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
2.86
0.81
39.51%
DE:CNW
co.don AG
0.02
-0.01
-44.44%
DE:MDG1
Medigene
0.02
-0.11
-85.71%
DE:HPHA
Heidelberg Pharma AG
2.65
-1.63
-38.08%
DE:FYB
Formycon AG
19.98
-6.67
-25.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.